APA (7th ed.) Citation

M, B., XS, Z., ZR, L., L, Y., RP, G., SS, Z., . . . Q, J. (2025). Efficacy, safety and predictive biomarker of third-generation tyrosine kinase inhibitors with azacitidine in myeloid blast phase of chronic myeloid leukemia. Cancer, 131(22), e70166. https://doi.org/10.1002/cncr.70166

Chicago Style (17th ed.) Citation

M, Bao, et al. "Efficacy, Safety and Predictive Biomarker of Third-generation Tyrosine Kinase Inhibitors with Azacitidine in Myeloid Blast Phase of Chronic Myeloid Leukemia." Cancer 131, no. 22 (2025): e70166. https://doi.org/10.1002/cncr.70166.

MLA (9th ed.) Citation

M, Bao, et al. "Efficacy, Safety and Predictive Biomarker of Third-generation Tyrosine Kinase Inhibitors with Azacitidine in Myeloid Blast Phase of Chronic Myeloid Leukemia." Cancer, vol. 131, no. 22, 2025, p. e70166, https://doi.org/10.1002/cncr.70166.